Literature DB >> 1438605

Clinical profile of clozapine: adverse reactions and agranulocytosis.

J A Lieberman1, A Z Safferman.   

Abstract

The arrival of clozapine has been one of the most significant developments in antipsychotic drug treatment since the advent of chlorpromazine ushered in the psychopharmacologic era. However, its utilization has been significantly limited and complicated by its potential to cause adverse effects and agranulocytosis in particular. It must be emphasized that clozapine has a side effect profile that is in many ways distinct from standard typical antipsychotic drugs. Side effects with clozapine are common and range from the benign to the potentially lethal. The most common side effects include sedation, dizziness, and sialorrhea during sleep; the most serious are agranulocytosis, seizures and respiratory depression. Although side effects from clozapine are not necessarily preventable, they are for the most part manageable. Even with the most serious adverse effects, proper knowledge of the medication's actions, clinical vigilance, and prompt intervention can prevent the occurrence of significant morbidity and mortality as a consequence of clozapine treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1438605     DOI: 10.1007/bf01064682

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  77 in total

1.  [Therapeutic method derived from hiberno-therapy in excitation and agitation states].

Authors:  J DELAY; P DENIKER; J M HARL
Journal:  Ann Med Psychol (Paris)       Date:  1952-07       Impact factor: 0.380

2.  Influence of patient-related variables on clozapine plasma levels.

Authors:  C Haring; W W Fleischhacker; P Schett; C Humpel; C Barnas; A Saria
Journal:  Am J Psychiatry       Date:  1990-11       Impact factor: 18.112

3.  Polypharmacy in fatal clozapine-associated agranulocytosis.

Authors:  S L Gerson; J A Lieberman; W R Friedenberg; D Lee; J J Marx; H Meltzer
Journal:  Lancet       Date:  1991-07-27       Impact factor: 79.321

4.  Apparent neuroleptic malignant syndrome with clozapine and lithium.

Authors:  H G Pope; J O Cole; P T Choras; C E Fulwiler
Journal:  J Nerv Ment Dis       Date:  1986-08       Impact factor: 2.254

5.  D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.

Authors:  L Farde; F A Wiesel; A L Nordström; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Adverse drug reactions with clozapine and simultaneous application of benzodiazepines.

Authors:  N Sassim; R Grohmann
Journal:  Pharmacopsychiatry       Date:  1988-11       Impact factor: 5.788

7.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 8.  Update on the clinical efficacy and side effects of clozapine.

Authors:  A Safferman; J A Lieberman; J M Kane; S Szymanski; B Kinon
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

9.  Clonidine inhibits salivary secretion by activation of postsynaptic alpha 2-receptors.

Authors:  M D Kaniucki; F J Stefano; C J Perec
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-07       Impact factor: 3.000

10.  Clozapine-induced agranulocytosis: a situation report up to August 1976.

Authors:  B Anderman; R W Griffith
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

View more
  19 in total

Review 1.  The use of psychotropics in the medically ill.

Authors:  M J Robinson; J L Levenson
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

Review 2.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

3.  Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

Authors:  L S Pilowsky; G F Busatto; M Taylor; D C Costa; T Sharma; T Sigmundsson; P J Ell; V Nohria; R W Kerwin
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 4.  Clozapine-induced sialorrhea: pathophysiology and management strategies.

Authors:  Samir Kumar Praharaj; Manu Arora; Sachin Gandotra
Journal:  Psychopharmacology (Berl)       Date:  2006-03-03       Impact factor: 4.530

Review 5.  Generic clozapine: a cost-saving alternative to brand name clozapine?

Authors:  Gordon Tse; Deborah Thompson; Ric M Procyshyn
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 6.  Adverse effects of clozapine in older patients: epidemiology, prevention and management.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

Review 7.  Adverse effects of antipsychotic drugs.

Authors:  A K Malhotra; R E Litman; D Pickar
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

Review 8.  Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.

Authors:  Mahmoud Slim; Inmaculada Medina-Caliz; Andres Gonzalez-Jimenez; M Rosario Cabello; Fermin Mayoral-Cleries; M Isabel Lucena; Raul J Andrade
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

9.  Mechanism of clozapine-induced agranulocytosis : current status of research and implications for drug development.

Authors:  M Pirmohamed; K Park
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

10.  Role of MKP-1 (DUSP1) in clozapine-induced effects on the ERK1/2 signaling pathway in the rat frontal cortex.

Authors:  Se Hyun Kim; Hyun Sook Yu; Hong Geun Park; Soyoung Park; Myoung Suk Seo; Won Je Jeon; Yong Min Ahn; Kyooseob Ha; Soon Young Shin; Yong Sik Kim
Journal:  Psychopharmacology (Berl)       Date:  2013-06-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.